Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hokusai-VTE: Edoxaban vs Warfarin for Symptomatic DVT and/or PE
NCT00986154Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2009
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 38
01
Overview
Phase 3, randomised, double-blind trial of edoxaban in deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Symptomatic Recurrent Venous Thromboembolism at 12 months. Started Oct 2009; status: completed.
02
Drugs
edoxaban
03
Conditions
deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT00986154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00986154.